M&A Deal Summary

VeriSIM Life Acquires Molomics Biotech

On May 11, 2022, VeriSIM Life acquired life science company Molomics Biotech

Acquisition Highlights
  • This is VeriSIM Life’s 1st transaction in the Life Science sector.
  • This is VeriSIM Life’s 1st transaction in Spain.

M&A Deal Summary

Date 2022-05-11
Target Molomics Biotech
Sector Life Science
Buyer(s) VeriSIM Life
Deal Type Add-on Acquisition

Target

Molomics Biotech

Barcelona, Spain
Molomics Biotech is a drug discovery and development company that uses Artificial Intelligence (AI) to create more efficacious drugs with fewer side effects. Molomics Biotech is based in Barcelona, Spain.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

VeriSIM Life

San Francisco, California, United States

Category Company
Sector Information Technology
DESCRIPTION

VeriSIM Life developed a sophisticated computational platform that leverages advanced AI and ML techniques to improve drug discovery and development by greatly reducing the time and money it takes to bring a drug to market. BIOiSIM™ is a first-in-class 'virtual drug development engine' that offers unprecedented value for the drug development industry by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illnesses or diseases. VeriSIM Life is based in San Francisco, California.


DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Spain M&A 1 of 1
Year: 2022 M&A 1 of 1